Growth hormone deficiency (GHD)

Growth Hormone
Somatrogon is a glycoprotein of recombinant DNA origin; it contains the sequence of amino acids with one copy of the C-terminal peptide found in human growth hormone.

1.Distribution: Pediatric patients: Vd: 0.812 L/kg.
2.Metabolism: Protein catabolism.
3.Half-life elimination: Pediatric patients: 28.3 hours.
4.Time to peak: SUBQ: Pediatric patients: 6 to 18 hours.

Hypersensitivity to somatrogon or any component of the formulation; acute critical illness after open heart surgery, abdominal surgery, multiple accidental trauma, or acute respiratory failure; closed epiphyses; active malignancy; diabetic retinopathy; patients with Prader-Willi syndrome who have severe obesity, severe respiratory impairment, history of upper airway obstruction, or history of sleep apnea.

1.Hematologic & oncologic: Eosinophilia (29%)
2.Immunologic: Antibody development (77%; neutralizing: 4%)
3.Local: Injection-site reaction
4.Nervous system: Headache (17%)
5.Respiratory: Nasopharyngitis (33%)
6.Miscellaneous: Fever (17%)

Growth hormone deficiency (GHD):
Children 3 to 11 years: SUBQ: 0.66 mg/kg/dose once weekly; individualize dose based on growth velocity, body weight, and insulin-like growth factor-1 (IGF-1); treat with the lowest effective dose. Discontinue treatment if there is evidence of epiphysial growth plate closure.